Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 17/20 | 0.59 |
| ▸ | CCNA1 | P78396 | 17/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | PAK4 | O96013 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17872164 | 0.89 | NTRK1 (0.60) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL28738725 | 0.86 | CDK2 (0.60) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL29574061 | 0.81 | CDK7 (0.46) | CDK2CCNA2CCNA1 | |
| SCHEMBL17872163 | 0.80 | NTRK1 (0.47) | CDK2CCNA2CCNA1CDK1CCNB1 | |
| SCHEMBL17872166 | 0.80 | ALDH1A1 (0.42) | CDK2CCNA2CCNA1 | |
| SCHEMBL29574348 | 0.79 | NPC1 (0.39) | CDK2CCNA2CCNA1NTRK1 | |
| SCHEMBL25947657 | 0.79 | CDK7 (0.38) | CDK2CCNA2CCNA1PAK4 | |
| SCHEMBL22164627 | 0.78 | LMNA (0.41) | CDK2CCNA2CCNA1 | |
| SCHEMBL31256518 | 0.78 | PAK4 (0.41) | CDK2CCNA2CCNA1NTRK1PAK4 | |
| SCHEMBL22164976 | 0.78 | PAK4 (0.41) | CDK2CCNA2CCNA1NTRK1PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4003335-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114401719-A | Inhibitors of cyclin-dependent kinase 7 and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK2, CDK5, CDK9 | CDK2 1/4885CCNA2 14/4885CCNA1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.